This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Actavis files opposition to motion for preliminary injunction in Nameda antitrust litigation

( October 30, 2014, 21:06 GMT | Official Statement) -- MLex Summary: Actavis and its subsidiary Forest Laboratories filed an opposition to New York's motion for preliminary injunction against the drugmakers over the Alzheimer's drug Nameda. The opposition argues that there is no evidence that switching to selling a newer version of the drug will cause harm because the new capsule has the benefit of only needing to be taken once a day and generic drugmakers will be able to sell their products. Defendants also say that the attorney general failed to establish he would succeed on the merits, failing to identify any legal duty that would require a company to continue to make and sell a product. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections